I am extremely pleased to add Mick and Bill to my leadership team. Their collective experience in driving success in sales and marketing, as well as their focus on customers, adds tremendous value to Quotient as we enter the U.S. market and align with customer needs and expectations
Newtown, PA (PRWEB) August 6, 2009
Quotient Biodiagnostics (Quotient) today announced the appointment of Michael (Mick) Hannan as Vice President, Marketing & Commercial Development and Bill Brady, as Vice President, Sales. They join Jeremy Stackawitz, President and CEO of Quotient and John Allan, Managing Director of Alba Bioscience to form the senior management team at Quotient.
Quotient is a member of the Quotient Bioscience Group, a leading provider of high value-added analytical and safety evaluation products and services for healthcare, bioscience and sport. Quotient plans to launch a full range of traditional blood-typing and screening products into the U.S. transfusion medicine market over the next twelve months. Incorporating its R&D and manufacturing operations at Alba Bioscience, Quotient has over 30 years experience in the transfusion medicine market. Quotient has a long record of, and remains committed to, developing new and innovative products to better serve the needs of its transfusion medicine customers.
Mick Hannan joins Quotient Biodiagnostics from GlaxoSmithKline (GSK), where he held a number of commercial roles (including leading multiple brands and a sales region) and played a key role in GSK's recent US acquisition strategy.
Bill Brady has held various senior management positions, most recently with Charter Medical, as Business Development Director for the Medical Filtration and Transfusion Therapy business, and Baxter Healthcare's Fenwal Division of North America, as an Area Vice President with its Biotech Division, where he was the East Area Director.
"I am extremely pleased to add Mick and Bill to my leadership team. Their collective experience in driving success in sales and marketing, as well as their focus on customers, adds tremendous value to Quotient as we enter the U.S. market and align with customer needs and expectations," said Jeremy Stackawitz.
Quotient was formed to commercialize the blood-typing reagent portfolio of Alba Bioscience, its R&D and manufacturing division. With its commitment to quality, service and value, Quotient's goal over the next twelve months is to enter the transfusion medicine market in North America with a full complement of traditional blood typing and screening products. A comprehensive range of monoclonal antibody products will be launched at the outset, with further blood-typing and screening products subsequently rolled out.
"We understand the pressures our customers face and their need to align and engage with reliable and service-oriented partners," said Stackawitz. "We believe our products and approach to customer care will enable us to become the partner of choice in the U.S. immunohematology market."
About Quotient Biodiagnostics:
Quotient Biodiagnostics is the diagnostics arm of Quotient Bioscience Group (United Kingdom) and incorporates Alba Bioscience, the Group's R&D and manufacturing business, which brings over 30 years experience in the transfusion medicine market to the Group. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient's goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation (initially in North America) to market and sell the Group's world leading range of blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.
For more information on Quotient Biodiagnostics products and services, contact 267-757-8778, or customer.service (at) quotientbiodiagnostics.com.